George Q. Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
George Q. Yang has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- Jimmy J. Caudell
Department of Radiation Oncology, Moffitt Cancer Center, Tampa, Florida
14 shared publications - Michelle Echevarria
Department of Radiation Oncology Moffitt Cancer Center & Research Institute Tampa Florida USA
14 shared publications - Christine H. Chung
Moffitt Cancer Center, Tampa, FL
13 shared publications - Anna Regina Giuliano
Center for Immunization and Infection Research in Cancer (CIIRC), H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
12 shared publications - Kedar Kirtane
Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, FL
12 shared publications - Antonio L. Amelio
Department of Head and Neck-Endocrine Oncology, Moffitt Cancer Center, Tampa, Florida
11 shared publications
Latest Publications
- 2 October 2026
- Published by Wiley in Head & Neck
Feasibility and Acceptability of Remote Symptom Monitoring and Wearable Activity Monitoring in Head and Neck Cancer Patients: A Mixed Methods Pilot Study
Background: Treatment‐related symptoms and toxicities are common in Head and Neck Cancer (HNC) patients undergoing chemoradiation (CRT). This underscores the importance of timely interventions and effective symptom and toxicity monitoring strategies to mitigate complications and improve quality of life (QoL). Traditional clinician and care team assessments often underreport patient symptoms, leading to urgent care and emergency room admissions, referred to as health care utilization (HCU). In contrast, electronically captured patient‐reported outcomes (ePROs) are associated with improved survival, better health‐related QoL, and lower HCU. Wearable activity monitors (WAMs) offer an additional method for continuous monitoring, enabling clinicians to detect symptoms and toxicities more efficiently and respond rapidly to patient needs. Methods: 12 HNC patients were assessed with ePROs and WAMs during CRT. Results: HNC patients undergoing CRT are receptive to ePRO and WAM‐based monitoring. Conclusions: HNC patients are receptive to participating in ePROs and WAM studies.
- 2 October 2026
- Published by Wiley in Head & Neck
Feasibility and Acceptability of Remote Symptom Monitoring and Wearable Activity Monitoring in Head and Neck Cancer Patients: A Mixed Methods Pilot Study
Background: Treatment‐related symptoms and toxicities are common in Head and Neck Cancer (HNC) patients undergoing chemoradiation (CRT). This underscores the importance of timely interventions and effective symptom and toxicity monitoring strategies to mitigate complications and improve quality of life (QoL). Traditional clinician and care team assessments often underreport patient symptoms, leading to urgent care and emergency room admissions, referred to as health care utilization (HCU). In contrast, electronically captured patient‐reported outcomes (ePROs) are associated with improved survival, better health‐related QoL, and lower HCU. Wearable activity monitors (WAMs) offer an additional method for continuous monitoring, enabling clinicians to detect symptoms and toxicities more efficiently and respond rapidly to patient needs. Methods: 12 HNC patients were assessed with ePROs and WAMs during CRT. Results: HNC patients undergoing CRT are receptive to ePRO and WAM‐based monitoring. Conclusions: HNC patients are receptive to participating in ePROs and WAM studies.
- 4 December 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (4) , 655-668
Cisplatin during radiation for head and neck cancer: insights from NRG Oncology experience
Background: Cisplatin remains the cornerstone radiosensitizer for definitive and adjuvant chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck. However, despite decades of clinical use, many practical aspects of cisplatin administration remain unstandardized in clinical practice and trials. Methods: Drawing on the collective experience of the NRG Oncology Head and Neck Working Group, this consensus article provides practical guidance on the administration of cisplatin during radiation therapy. We review and propose recommendations regarding the timing of chemotherapy and radiation initiation, premedication and hydration regimens by dose, monitoring and grading of cisplatin-induced ototoxicity, and management strategies during cisplatin shortages. Our guidance is informed by clinical trial protocols, retrospective and prospective data, and multidisciplinary expert consensus. We emphasize the importance of protocol flexibility to support equitable trial accrual, minimize treatment delays, and improve patient-centered outcomes. Conclusions: This article offers a unified framework to optimize the use of cisplatin in chemoradiation protocols, improve adherence, reduce toxicity, and preserve oncologic efficacy. Our recommendations are particularly timely in the context of evolving clinical practices and recent cisplatin shortages. Insights from the NRG Oncology collaborative group aim to inform future trial designs and clinical practice guidelines, ensuring consistent and equitable care for patients with head and neck cancer.
- 4 December 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (4) , 655-668
Cisplatin during radiation for head and neck cancer: insights from NRG Oncology experience
Background: Cisplatin remains the cornerstone radiosensitizer for definitive and adjuvant chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck. However, despite decades of clinical use, many practical aspects of cisplatin administration remain unstandardized in clinical practice and trials. Methods: Drawing on the collective experience of the NRG Oncology Head and Neck Working Group, this consensus article provides practical guidance on the administration of cisplatin during radiation therapy. We review and propose recommendations regarding the timing of chemotherapy and radiation initiation, premedication and hydration regimens by dose, monitoring and grading of cisplatin-induced ototoxicity, and management strategies during cisplatin shortages. Our guidance is informed by clinical trial protocols, retrospective and prospective data, and multidisciplinary expert consensus. We emphasize the importance of protocol flexibility to support equitable trial accrual, minimize treatment delays, and improve patient-centered outcomes. Conclusions: This article offers a unified framework to optimize the use of cisplatin in chemoradiation protocols, improve adherence, reduce toxicity, and preserve oncologic efficacy. Our recommendations are particularly timely in the context of evolving clinical practices and recent cisplatin shortages. Insights from the NRG Oncology collaborative group aim to inform future trial designs and clinical practice guidelines, ensuring consistent and equitable care for patients with head and neck cancer.
- Open Access
- 13 November 2025
- Published by SAGE Publications in Cancer Control
- Vol. 32
Impacts of a Novel Digital Education Module for Oncology Patients: A Prospective Experience
Introduction: Cancer patients often face challenges retaining critical information related to their diagnosis and treatment plans, with studies reporting retention rates as low as 11%–25%. This knowledge gap can negatively impact treatment adherence and increase patient anxiety. Visual communication tools may enhance patient comprehension and engagement in cancer care. To evaluate the effectiveness of MyCaregorithm, a novel digital tool, in improving patient comprehension of cancer treatment plans in a radiation oncology clinic setting. Methods: Adult patients with head and neck, prostate, or pancreatic cancers were recruited during routine clinic visits. Radiation oncologists or advanced practice providers utilized MyCaregorithm to explain the diagnosis, treatment plans, potential side effects, and follow-up care. Patients completed a survey assessing their experience with the tool. Descriptive statistics were used to analyze the data. Results: The study included patients with head and neck (69%), prostate (17%), and pancreatic (14%) cancers. Key findings include: 94% of patients reported improved understanding of treatment options 94% found visual images enhanced comprehension of their medical situation 85% experienced greater benefit compared to previous consultations without the tool 97% would recommend the tool to other patients. Conclusion: The digital technology tool demonstrated high effectiveness in improving patient comprehension and engagement across multiple cancer types. The consistently positive response rates highlights its potential to enhance patient-provider communication in oncology settings. Further studies with larger cohorts are needed to validate these promising results.
- 13 November 2025
- Published by SAGE Publications in Cancer Control
- Vol. 32
Open AccessImpacts of a Novel Digital Education Module for Oncology Patients: A Prospective Experience
Introduction: Cancer patients often face challenges retaining critical information related to their diagnosis and treatment plans, with studies reporting retention rates as low as 11%–25%. This knowledge gap can negatively impact treatment adherence and increase patient anxiety. Visual communication tools may enhance patient comprehension and engagement in cancer care. To evaluate the effectiveness of MyCaregorithm, a novel digital tool, in improving patient comprehension of cancer treatment plans in a radiation oncology clinic setting. Methods: Adult patients with head and neck, prostate, or pancreatic cancers were recruited during routine clinic visits. Radiation oncologists or advanced practice providers utilized MyCaregorithm to explain the diagnosis, treatment plans, potential side effects, and follow-up care. Patients completed a survey assessing their experience with the tool. Descriptive statistics were used to analyze the data. Results: The study included patients with head and neck (69%), prostate (17%), and pancreatic (14%) cancers. Key findings include: 94% of patients reported improved understanding of treatment options 94% found visual images enhanced comprehension of their medical situation 85% experienced greater benefit compared to previous consultations without the tool 97% would recommend the tool to other patients. Conclusion: The digital technology tool demonstrated high effectiveness in improving patient comprehension and engagement across multiple cancer types. The consistently positive response rates highlights its potential to enhance patient-provider communication in oncology settings. Further studies with larger cohorts are needed to validate these promising results.
- Open Access
- 22 July 2025
- Published by American Association for Cancer Research (AACR)
Table 1 from Plasma Cell-Free Human Papillomavirus DNA and Oral Gargle HPV DNA in Patients with HPV-Related Oropharyngeal Cancer Treated with Radiotherapy
Baseline patient characteristics
- 22 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Plasma Cell-Free Human Papillomavirus DNA and Oral Gargle HPV DNA in Patients with HPV-Related Oropharyngeal Cancer Treated with Radiotherapy
Baseline patient characteristics
- Open Access
- 22 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Plasma Cell-Free Human Papillomavirus DNA and Oral Gargle HPV DNA in Patients with HPV-Related Oropharyngeal Cancer Treated with Radiotherapy
Supplemental Figure 1: Trial Schema and Timepoints of Sample Collection. Oral gargle samples were collected at weekly intervals from baseline to week 4, then at end of treatment and at 3, 6, and 12 months after treatment. Plasma samples were collected at baseline, week 4, end of treatment, and at 3, 6, 12, 18, and 24 months after treatment. Imaging studies done at week 4 was used to assess %reduction of target tumor volume at week 4.
- 22 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Plasma Cell-Free Human Papillomavirus DNA and Oral Gargle HPV DNA in Patients with HPV-Related Oropharyngeal Cancer Treated with Radiotherapy
Supplemental Figure 1: Trial Schema and Timepoints of Sample Collection. Oral gargle samples were collected at weekly intervals from baseline to week 4, then at end of treatment and at 3, 6, and 12 months after treatment. Plasma samples were collected at baseline, week 4, end of treatment, and at 3, 6, 12, 18, and 24 months after treatment. Imaging studies done at week 4 was used to assess %reduction of target tumor volume at week 4.
- Open Access
- 22 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Plasma Cell-Free Human Papillomavirus DNA and Oral Gargle HPV DNA in Patients with HPV-Related Oropharyngeal Cancer Treated with Radiotherapy
Supplemental Figure 4: Oral Gargle HPV DNA Collected at Weekly Intervals from Weeks 1 to 4 and Their Associations with Reduction of Target Tumor Volume (TTV) at Week 4. A) Comparison of the reduction of TTV at week 4 in patients with versus without week 4 oral gargle cfHPV DNA clearance; B) week 1 oral gargle cfHPV DNA clearance; C) week 2 oral gargle cfHPV DNA clearance; and D) week 3 oral gargle cefHPV DNA clearance. Positive (i.e. >0) numbers represent tumor volume reduction while negative (i.e. <0) numbers represent tumor volume increase. Statistical test represents Mann-Whitney Test between the 2 groups overlaid by the bolded line. The median and upper and lower quartiles are represented in the bar graphs.
- 22 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Plasma Cell-Free Human Papillomavirus DNA and Oral Gargle HPV DNA in Patients with HPV-Related Oropharyngeal Cancer Treated with Radiotherapy
Supplemental Figure 4: Oral Gargle HPV DNA Collected at Weekly Intervals from Weeks 1 to 4 and Their Associations with Reduction of Target Tumor Volume (TTV) at Week 4. A) Comparison of the reduction of TTV at week 4 in patients with versus without week 4 oral gargle cfHPV DNA clearance; B) week 1 oral gargle cfHPV DNA clearance; C) week 2 oral gargle cfHPV DNA clearance; and D) week 3 oral gargle cefHPV DNA clearance. Positive (i.e. >0) numbers represent tumor volume reduction while negative (i.e. <0) numbers represent tumor volume increase. Statistical test represents Mann-Whitney Test between the 2 groups overlaid by the bolded line. The median and upper and lower quartiles are represented in the bar graphs.
- Open Access
- 22 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Plasma Cell-Free Human Papillomavirus DNA and Oral Gargle HPV DNA in Patients with HPV-Related Oropharyngeal Cancer Treated with Radiotherapy
Supplemental Figure 2: Association of Baseline Clinical Characteristics with Plasma and Oral Gargle HPV DNA Status. Bar charts show the comparison of proportions of patients with A) detectable versus undetectable baseline plasma cfHPV DNA or B) detectable versus undetectable baseline oral gargle HPV DNA stratified by key baseline clinical variable groups. P-values represent Fisher’s Exact Tests where p < 0.05 is considered significant.
- 22 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Plasma Cell-Free Human Papillomavirus DNA and Oral Gargle HPV DNA in Patients with HPV-Related Oropharyngeal Cancer Treated with Radiotherapy
Supplemental Figure 2: Association of Baseline Clinical Characteristics with Plasma and Oral Gargle HPV DNA Status. Bar charts show the comparison of proportions of patients with A) detectable versus undetectable baseline plasma cfHPV DNA or B) detectable versus undetectable baseline oral gargle HPV DNA stratified by key baseline clinical variable groups. P-values represent Fisher’s Exact Tests where p < 0.05 is considered significant.
- Open Access
- 22 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Plasma Cell-Free Human Papillomavirus DNA and Oral Gargle HPV DNA in Patients with HPV-Related Oropharyngeal Cancer Treated with Radiotherapy
Supplemental Figure 3: Week 4 Plasma Cell-Free HPV (cfHPV) or Oral Gargle HPV DNA and its Association with Progression-free Survival (PFS). A) Comparison of PFS for patients with versus without week 4 plasma cfHPV DNA clearance. B) Comparison of PFS for patients with versus without week 4 oral gargle cfHPV DNA clearance. Log-rank test represents a comparison between the respective groups.
- 22 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Plasma Cell-Free Human Papillomavirus DNA and Oral Gargle HPV DNA in Patients with HPV-Related Oropharyngeal Cancer Treated with Radiotherapy
Supplemental Figure 3: Week 4 Plasma Cell-Free HPV (cfHPV) or Oral Gargle HPV DNA and its Association with Progression-free Survival (PFS). A) Comparison of PFS for patients with versus without week 4 plasma cfHPV DNA clearance. B) Comparison of PFS for patients with versus without week 4 oral gargle cfHPV DNA clearance. Log-rank test represents a comparison between the respective groups.
- Open Access
- 22 July 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from Plasma Cell-Free Human Papillomavirus DNA and Oral Gargle HPV DNA in Patients with HPV-Related Oropharyngeal Cancer Treated with Radiotherapy
Waterfall plot showing the % change of week 4 TTV compared with baseline for all patients who met the inclusion criteria (N = 50). Each legend at the bottom of the waterfall plot show the status of HPV DNA clearance for oral gargle at weekly intervals for weeks 1 to 4 and for plasma at week 4; baseline HPV DNA status by plasma and oral gargle; and the locoregional disease-free survival (LRFS), distant metastatic disease-free survival (DMFS) recurrence, and PFS statuses at 24 months after treatment of individual patients.
- 22 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Plasma Cell-Free Human Papillomavirus DNA and Oral Gargle HPV DNA in Patients with HPV-Related Oropharyngeal Cancer Treated with Radiotherapy
Waterfall plot showing the % change of week 4 TTV compared with baseline for all patients who met the inclusion criteria (N = 50). Each legend at the bottom of the waterfall plot show the status of HPV DNA clearance for oral gargle at weekly intervals for weeks 1 to 4 and for plasma at week 4; baseline HPV DNA status by plasma and oral gargle; and the locoregional disease-free survival (LRFS), distant metastatic disease-free survival (DMFS) recurrence, and PFS statuses at 24 months after treatment of individual patients.